P
ercutaneous coronary intervention (PCI) using coronary stents is a universal and established therapeutic modality in the management of symptomatic coronary artery disease. However, in-stent restenosis (ISR) requiring recurrent revascularization remains the Achilles heel of this procedure. 1 Drug-eluting stents (DES) are associated with a much lower incidence of ISR compared with bare metal stents (BMS), with reported rates between 5% and 10% at 1 year. 2 Unlike the diffuse restenosis seen with BMS, ISR associated with DES tends to be focal and frequently occurs at the proximal edge of the stent. 3 Despite these apparent differences in morphology, factors implicated in the etiopathogenesis of ISR with both DES and BMS are remarkably similar, namely, the type of lesion, patient characteristics, and procedurerelated considerations. These factors culminate in a final common pathway of neointimal hyperplasia with smooth muscle proliferation and late vessel remodeling, resulting in narrowing of the stented segment.
The cardiologist's armamentarium is replete with a variety of options to deal with this complication: plain old balloon angioplasty, drug-coated balloon angioplasty, cutting balloon angioplasty, use of atherectomy devices, and repeat stenting with another DES. Despite these diverse possibilities, the treatment of DES-ISR presents a formidable challenge because of the recurring nature of these lesions. 4 Intravascular brachytherapy (IVBT) was previously approved for the treatment of BMS restenosis based on the favorable outcome reported in multiple randomized trials. 5, 6 The popularity of brachytherapy, however, waned with the introduction of DES because of the logistic difficulties and noticeable reduction in restenosis with these newer stents. 7 Nevertheless, with the limited rescue options available for recurrent DES failure, our catheterization laboratory initiated IVBT program for this indication based on positive results shown in pilot studies. 8 In this analysis, we aim to portray the efficacy, safety, and clinical outcomes associated with IVBT in patients with recurrent DES restenosis with multimetal layers when compared with other conventional treatment modalities (non-IVBT group).
METHODS

Study Population
This analysis comprised patients selected from an institutional review board-approved prospective interventional cardiology registry from our institution from 2011 to 2015. Informed consent for this study was obtained from all the included patients. The study included consecutive patients with anginal symptoms or ischemia on noninvasive tests undergoing PCI for recurrent DES restenosis with at least 2 layers of stents at the restenosis location ( Figure 1 ). We included only those patients with the last layer of stent confirmed to be a DES in this analysis; however, the index stent(s) could be BMS or DES. Patients presenting with stent thrombosis (ST) and those with cardiogenic shock were excluded. In patients who had multiple procedures which matched the study selection criteria, only the first procedure was counted in for the analysis. The baseline clinical characteristics, details of prior PCI, laboratory results, procedural information, and in-hospital clinical events were collected from the data entered in our PCI registry. The follow-up was gathered during either hospital visits or phone by dedicated research staff at 30 days and 1 year after the procedure.
Procedure
PCI for recurrent ISR was performed according to the contemporary best practice procedure guidelines using either heparin or bivalirudin anticoagulation. All patients received a loading dose of aspirin and a thienopyridine agent immediately before the procedure. If required, adjunctive pharmacotherapy with glycoprotein IIb/IIIa inhibitors was used at operator's discretion.
Adequate lesion preparation was achieved by predilatation using either noncompliant balloon, cutting balloon, or both. Use of atherectomy was also performed in some cases as per operator's preference. Repeat stenting with a DES was performed in a subset of patients in the control arm while stenting concurrent with brachytherapy was avoided in the IVBT arm. Postdilatation at high pressures using noncompliant balloon was done whenever a new DES was implanted.
After the lesion preparation, patients in the brachytherapy arm received localized radiation using the Novoste Beta-Cath 3.5F system (Best Vascular Inc, Springfield, VA) using a strontium-90/yttrium-90 isotope. This radioactive isotope produces β-particles and has a half-life of 28.8 years and energies up to 2.27 MeV. Radiation was delivered using a triple lumen closed end catheter with radiopaque markers such that the source covered at least 5 mm on either side of the lesion. Source length of 30, 40, or 60 mm were used based on the target
WHAT IS KNOWN
• A vast majority of in-stent restenosis in the current era are managed by repeat stenting with drugeluting stents.
• Unfortunately, ≈1 in 6 patients treated with 2 layers of stents presents with symptomatic recurrences requiring revascularization.
• Such multilayer in-stent restenosis is a challenging clinical problem with no clear evidence-based therapy available.
• Retrospective studies have shown the feasibility of intravascular brachytherapy in treating recurrent drug-eluting stent restenosis.
WHAT THE STUDY ADDS
• Our analysis found that intravascular brachytherapy offers a significant advantage in reducing target lesion revascularization and major adverse cardiac events at 1 year when compared with other percutaneous options for the treatment of multilayer drug-eluting stents restenosis.
lesion length. Radiation dosage was determined based on the diameter of the vessel and ranged from 18.4 to 23 Gy from the center of the source. Dwell time, calculated based on lesion length and vessel diameter, usually ranged between 200 and 300 seconds. At the culmination of the procedure, the source was retracted, and the catheter was removed from the body. A room survey was performed at the end to confirm that no isotope remained outside the catheter. A radiation oncologist oversaw the entire procedure following Nuclear Regulatory Commission guidelines. 9 After the procedure, the patients in the control arm received dual antiplatelet therapy with aspirin and a thienopyridine agent for at least 1 year; however, in patients who received IVBT, this was continued for 3 years.
Study Definitions
Binary angiographic ISR was defined as >50% narrowing within the stent or 5 mm of its edges. Target lesion revascularization was defined as revascularization involving the stented segment or within 5 mm of the proximal or distal end of the stent while target vessel revascularization (TVR) specified either percutaneous or surgical revascularization of the stented vessel. Universal definition criteria were used for identifying myocardial infarctions (MI). 10 Adjudication of ST was done as per the Academic Resort Consortium criteria. 11 Major adverse cardiac events (MACE) was defined as a composite of all-cause death, MI, and target lesion revascularization. Similarly, TVR-MACE was defined as composite of all-cause death, MI, and TVR. A procedure was deemed angiographically successful if the final angiogram showed <30% residual stenosis with Thrombolysis in Myocardial Infarctions flow grade 3 down the target vessel.
End Points
The primary end point of the study was the occurrence of MACE at 1 year of follow-up. The incidence of the individual components of the MACE, TVR-MACE, and ST formed the various secondary end points of the study.
Statistical Analysis
Continuous variables are presented as the mean±SD or as the median±interquartile range (25th-75th percentiles) based on the normality of their distribution. Comparison of continuous variables between the 2 groups was done using Student t test or Mann-Whitney U test. Categorical variables, expressed as numbers and percentages, were compared using Fisher exact test or χ 2 test. All reported P values are 2 sided, and a P<0.05 was deemed statistically significant. Kaplan-Meier method was used to estimate the cumulative incidence of clinical events per patient, and the intergroup difference was assessed using the log-rank test.
To further validate our findings, we executed a 1 to 1 matching based on estimated propensity score for each patient. The score was calculated using binary logistic regression, using as covariates clinical and procedural variables that were clinically pertinent for developing restenosis: age, sex, diabetes mellitus, hypertension, hyperlipidemia, chronic kidney disease on dialysis, prior history of coronary artery bypass surgery, time since last restenosis, number of stent layers, and generation of DES. The nearest neighbor matching was done randomly, and analysis was performed to assess the 1-year clinical endpoints. The Hosmer and Lemeshow goodness of fit model was evaluated to test the calibration of the model. Finally, covariate-adjusted hazard ratios of various clinical outcomes were calculated for this matched cohort.
RESULTS
Baseline Characteristics
A total of 2714 patients underwent PCI at our center for treating DES restenosis during the study period, of which 328 patients fit the selection criteria of our analysis. Among these patients, 197 patients underwent IVBT while the rest were included in the control arm (non-IVBT). Six patients in the IVBT group received >1 brachytherapy procedure (5 in a different vessel and 1 for the same vessel), but only the index procedure was used for analysis. Eight patients in the IVBT arm and 2 patients in the control arm received the intervention of 2 vessels during the index procedure. Both the groups were comparable concerning most of the baseline clinical features (Table 1) . Both hypertension and hyperlipidemia were present in nearly all the patients in this high-risk coronary artery disease cohort. The latter was statistically more common in the brachytherapy arm (100% and 97%; P=0.03). Prior history of coronary artery bypass surgery was more common in patients who underwent IVBT (50% in IVBT arm versus 27% in the control arm; P <0.01). MI as the presenting feature was more frequent in the control arm (2% in IVBT arm and 8% in control arm; P=0.02). No difference was noted with regard to important restenosis related risk factors, such as diabetes mellitus, use of insulin, or chronic kidney disease requiring dialysis. Table 2 shows the comparison between the 2 groups on the procedural data. IVBT was used more often than not for the treatment of recurrent ISR involving both arterial grafts and venous grafts (19% and 2%). A significant majority of patients in the entire cohort had only 2 layers of metal at the lesion location. Patients with ≥3 stent layers were more often treated with radiation although this missed statistical significance (26% and 15%; P=0.06). More than half of the patients in both the groups had ≥4 PCIs performed for the index lesion including at least 2 layers of stent placement. However, the exact number of prior PCIs was unclear in some of the included patients; this being more common in the IVBT arm (18% and 5%). The last stent that failed was a second-generation DES in ≈85% of patients in both the groups. There was no intergroup difference in either the mean length (22.7±7.5 mm in IVBT arm and 21.8±6.7 mm in the control arm; P=0.27) or the mean diameter (3.0±0.4 in both the groups; P=0.27) of the last implanted DES. The mean time since the previous PCI involving the index lesion was also similar in both the groups (465±367 days in the IVBT group and 508±310 days in the control group; P=0.27).
Lesion Characteristics and Procedural Features
Lesion preparation was performed using either noncompliant balloon or cutting balloon, and this was similar in both the groups. Approximately one-fifth of the total patients underwent atherectomy for optimal preparation ( Table 2) . Repeat stenting with a DES was done in 47% patients in the non-IVBT arm. However, in the IVBT procedures, concurrent stenting with a DES was done only in one patient.
Clinical Outcome
Immediate angiographic success was achieved in all the 328 patients treated for recurrent DES restenosis, and all were discharged alive from the hospital. There was no immediate periprocedural complication attributed to the use of brachytherapy catheter in the patients who underwent IVBT. The clinical outcome parameters at 1 year are listed in Table 3 . The primary end point of 1-year MACE was significantly lower in the IVBT arm in comparison to controls (13.2% and 28.2%; P=0.01). Similarly, the TVR-MACE rates was numerically lower in the IVBT arm (17.8% and 29%; P=0.09). No significant difference was noted in either death, MI, or ST rates between the groups at 1 year in this analysis. KaplanMeier survival analysis (Figure 2 ) revealed that 1-year MACE was significantly lower in patients treated with IVBT (log-rank P≤0.01).
Propensity Score Match Analysis
We identified 91 pairs of patients by propensity score score matching who were well balanced for the baseline clinical and procedural characteristics (Tables 1 and 2 ).
The 1-year clinical outcomes are listed in Table 3 
DISCUSSION
This investigation is the largest contemporary analysis comparing safety and efficacy of vascular brachytherapy with other modalities in the treatment of recurrent multilayer DES-ISR. Our research indicates that brachytherapy offers an improved MACE rate at 1 year in comparison with other conventional methods for the treatment of recurrent DES-ISR. It also proves the feasibility and safety of IVBT in managing this difficult to treat subset of patients with recalcitrant restenosis. Brachytherapy, although initially approved for BMS-ISR, is currently almost exclusively used for DES restenosis. The process of restenosis is similar to proliferative wound healing, which is sensitive to low dose radiation. 12 IVBT aims to deliver a uniform amount of low radiation dose to impede new intimal cell growth at target arterial segment without causing damage to healthy surrounding tissue. 13 This is achieved by both direct ionizing emission-induced damage as well as free radical-mediated injury resulting in reducing cell proliferation in the media and adventitia.
14 Radiation also exerts positive effects on restenosis with its myriad of anti-inflammatory activities, such as decreasing chemotaxis and inhibition of leucocyte migration, cytokine production, and macrophage activity. 15 There are, however, specific concerns on IVBT which were shown during the BMS era: (1) higher incidence of edge restenosis likely to be because of the geographic mismatch between area covered by radiation and zone of injury, (2) late catch-up phenomenon causing late lumen loss leading to equipoise in efficacy on long-term follow-up, and (3) late ST especially with concurrent stent placement. The higher rate of late ST seen in previous studies 16 can be explained by the delay in reendothelialization caused by radiation in combination with the unavailability of contemporary dual antiplatelet therapy at that time. The introduction of DES seems to be the answer to many of these apprehensions leading to their use in treating BMS restenosis. High-quality randomized investigations comparing DES and brachytherapy also favored the former, ultimately leading to DES placement as the treatment of choice for BMS-ISR. 7, 17 DES scored over IVBT in these trials because of more significant immediate lumen gain and lesser late lumen loss in the longer term.
The overall increase in PCI procedures in the recent years along with the ubiquitous adoption of DES has led a significant increase in the absolute number of patients with DES restenosis. There are multiple observational and randomized trials assessing the efficacy of various options for treating DES restenosis. Current evidence suggests that repeat stenting with a second-generation DES and drug-eluting balloons is the best options available for managing the first episode of DES-ISR. 18 Because drug-eluting balloons are yet to be approved for this indication in the United States, a significant majority of these patients are treated with a newer DES. Unfortunately, studies indicate that DES restenotic lesions tend to have higher recurrences than that of BMS restenosis when both are treated with DES. 19 More than 15% of these patients already treated with 2 layers of metallic stents presents with symptomatic recurrences requiring revascularization. 20 At present, there is a paucity of data on how best to treat these multilayer DES restenosis. Use of IVBT in this scenario is theoretically advantageous given the hazards of ST and recurrence of restenosis with multiple stent layers.
Our literature search did not reveal any head to head comparison between IVBT and other modalities in the treatment of multilayer stent restenosis. A single retrospective study has previously reported the clinical outcomes of brachytherapy in comparison with other alternatives, including conventional balloon angioplasty and repeat stenting in treating DES failure. 21 Majority of the patients included in this analysis had only one layer of stents at the site of lesion (mean, 1.2±0.5), thus representing a considerably lower risk cohort for recurrence. This analysis failed to find any difference in clinical events including target lesion revascularization at 1 year between the treatment groups. The long-term outcomes of IVBT in recurrent DES failure were recently reported by the same research group. In this single arm retrospective analysis of DES-ISR (64% being first-generation DES), a majority of patients had at least 3 to 4 episodes of restenosis. They reported a TVR of 19.1% at 1 year and 30.5% at 3 years in this high-risk cohort. 22 Nevertheless, the absence of a control arm in this study makes it difficult to establish the efficacy of IVBT vis-avis other options for treating DES restenosis.
The patients included in our study represent a high-risk group for restenosis given the high prevalence of clinical risk factors. Furthermore, the presence of multiple layers of stents, as well as the high number of prior procedures for restenosis, makes the risk of recurrence exceptionally high. Our analysis demonstrates the advantages of brachytherapy in preventing restenosis as well as MACE at 12-month follow-up in this very high-risk cohort. Late ST, the foremost worry during the BMS era, was not realized in our study with rates <1%. This is comparable to other contemporary studies of IVBT and is likely because of the recent advances in antiplatelet therapy. 22 Because IVBT was commonly offered when all other alternatives are exhausted, this group had higher risk factors for recurrences as is evident from the baseline features. The advantages seen with IVBT over conventional modalities despite these adverse features gives credence to their role in managing recalcitrant restenosis involving multiple stent layers.
Strengths and Limitations
This is the first study that compared brachytherapy with other conventional modalities in treating patients with restenosis involving multiple stent layers. The major limitation of this analysis is its retrospective nature; the decisions on the choice of treatment were not random but based on the operator's preference. The corroboration of the advantages of IVBT in the propensity score-matched cohort analysis, however, validates our conclusions. Intracoronary imaging was used only in a minority of included patients, thus limiting our ability to assess the mechanism of DES restenosis. Finally, we followed the patients for 1 year which is a relatively short period to capture delayed events such late catchup phenomenon and very late ST.
Conclusions
Recurrence of coronary restenosis after multiple metal layers of stents remains a vexing problem of the current era. Our analysis reveals that IVBT offers significant value in this situation by reducing restenosis as well as MACE at the same time providing exceptional safety profile at 1-year follow-up. However, comparative trials with long-term follow-up are needed to rule out concerns, such as late catch-up phenomenon and very late ST. 
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